Invex Therapeutics (ASX:IXC) Institutional Ownership: 0.01% (As of Jul. 02, 2026)


What is Invex Therapeutics Institutional Ownership?

Invex Therapeutics ASX:IXC +5.56% Institutional Ownership is 0.01% as of Jul. 02, 2026. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Invex Therapeutics's institutional ownership is 0.01%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Invex Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Invex Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Invex Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Institutional Ownership Chart

Invex Therapeutics Historical Data

The historical data trend for Invex Therapeutics can be seen below:

2021-05-31 2021-06-30 2021-07-31 2021-08-31 2021-09-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30
Institutional Ownership 0.08 0.08 0.08 0.08 0.08 0.01 0.01 0.01 0.01 0.01

Invex Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.01% mean?
Invex Therapeutics (ASX:IXC) has a Institutional Ownership of 0.01% as of Jul. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Invex Therapeutics and its competitors.
Is Invex Therapeutics' Institutional Ownership too high?
Invex Therapeutics' current Institutional Ownership is 0.01%.
How does Invex Therapeutics' Institutional Ownership compare to VRTX and REGN?
Invex Therapeutics' Institutional Ownership of 0.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Invex Therapeutics and its competitors. Invex Therapeutics's current Institutional Ownership is 0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Institutional Ownership of 0.01%. The current Institutional Ownership is 0.01%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Institutional Ownership is 0.01% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.